Martin Bachmann

Martin Bachmann is a Visiting Professor of Vaccinology at the Nuffield Department of Medicine, University of Oxford, with research groups focused on Chronic Pain and Parkinson's Disease. His work centers on developing innovative vaccine platforms using virus-like particles (VLPs) for therapeutic applications beyond traditional infectious diseases.

His primary research interests include immunology, vaccinology, and the mechanistic role of epitope repetitiveness as a geometric pathogen-associated molecular pattern (PAMP). He demonstrated how repetitive structures enhance B cell responses through receptor cross-linking and innate immune recruitment, explaining viral/bacterial immunogenicity. His VLP-based platform has achieved clinical proof-of-concept for hypertension, smoking cessation, allergies, asthma, and melanoma, with ongoing industry programs for Alzheimer's disease (Novartis) and allergy (Pfizer).

Analysis of his 2018-2019 publications reveals a strategic shift toward therapeutic vaccines for chronic conditions, including neurodegenerative disorders and pain management. His work bridges preclinical validation with human clinical trials, emphasizing cross-disciplinary applications of immunology in non-infectious disease contexts through partnerships with Novartis, Pfizer, and A*Star Singapore.

Prof. Bachmann has initiated multiple clinical trials and secured significant industry collaborations, including Novartis' Alzheimer's program and Pfizer's allergy initiatives. His research group develops novel technologies such as mammalian cell display for functional genomics and methods for isolating fully human antibodies, demonstrating substantial translational research funding despite no specific grant details being listed.

He leads dedicated research teams within Oxford's Nuffield Department of Medicine focusing on Chronic Pain and Parkinson's Disease. His laboratory specializes in VLP engineering, epitope conjugation techniques, and adjuvant development using toll-like receptor 9 ligands, with recent work exploring cytokine modulation and neuroimmune interactions for chronic condition management.